Updated Story President Joe Biden will sign an executive order Wednesday (Feb. 24) afternoon calling for a 100-day review of the U.S. pharmaceutical supply chain in a bid to protect finished drug products and active pharmaceutical ingredients against a range of vulnerabilities, including over reliance on foreign competitors and diminished capacity. The order will require federal agencies to consult with industry and academia as part of the initial review, which White House officials told reporters should help...